Welcome To Diurnal

Diurnal is a UK-based specialty pharmaceutical company dedicated to developing high-quality hormone therapeutics to aid lifelong treatment for rare and chronic endocrine conditions, including Congenital Adrenal Hyperplasia, Adrenal Insufficiency, Hypogonadism and Hypothyroidism.

The company has a strong, multi-skilled entrepreneurial management team with extensive pharmaceutical product development experience and an affiliated network of world-class clinical experts in the area of endocrinology.

Mission Statement

To address the major unmet clinical and patient needs in endocrinology by creating high quality products for the lifelong treatment of chronic conditions.

Latest News

  • 04 Aug
    2015

    Diurnal extends its Cooperative Research and Development Agreement with the National Institutes of Health

    Cardiff, UK – Diurnal Limited is pleased to announce an extension to its existing Cooperative Research and Development ...

    Read More

  • 01 Jul
    2015

    Diurnal Ltd appoints Peter Allen as Chairman

    Cardiff, UK – Diurnal Limited, the global specialty pharmaceutical company developing therapies for chronic endocrine d...

    Read More

  • 19 May
    2015

    FDA grants Orphan Drug Designation to Diurnal for Infacort®

    Cardiff, UK - Diurnal Limited (“Diurnal” or “the Company”) today announced that it has been granted Orphan Drug Designa...

    Read More